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ABSTRACT
Heme oxygenase-1 (HO-1) degrades heme to bilirubin. In addition, it is 
upregulated in malignant disease and has been described as an important factor for 
cancer prognosis and therapy. Under physiological conditions HO-1 is anchored to 
the endoplasmic reticulum (ER). Under stress conditions HO-1 can be cleaved and 
subsequently translocates to the cytosol and nucleus.
In this study we systematically investigated the influence of HO-1’s catabolic 
activity and subcellular localization on resistance against the tyrosine kinase inhibitor 
imatinib in leukemia cells by confocal laser scanning microscopy, hemoglobin synthesis 
experiments and cell viability assays. We created two types of monoclonal K562 cell 
lines stably transfected with GFP-tagged HO-1: cell lines expressing ER anchored 
HO-1 or anchorless HO-1. Since translocation of HO-1 disrupts the association with 
cytochrome P450 reductase, heme degrading activity was higher for ER anchored 
versus anchorless HO-1. Cell viability tests with increasing concentrations of imatinib 
showed IC50-values for all six cell lines with ER localized HO-1 that were similar to 
control cells. However, out of the seven cell lines with anchorless HO-1, two showed 
a statistically significant increase in the imatinib IC50 (19.76 μM and 12.35 μM versus 
2.35 – 7.57 μM of sensitive cell lines) corresponding to plasma concentrations outside 
the therapeutic range.
We conclude that the presence of translocated HO-1 in the cytosol and nucleus 
supports imatinib resistance while it is not sufficient to cause imatinib resistance in 
every cell line. In contrast, an increase in ER anchored HO-1 with high heme degrading 
activity does not contribute to imatinib resistance.
INTRODUCTION
Heme oxygenase-1 (HO-1), an inducible heme 
degrading enzyme important for iron hemostasis and 
oxidative stress response, emerges as a novel target of 
cancer therapy [1]. HO-1 is upregulated in prostate cancer 
[2, 3], pancreas carcinoma [4], myeloid leukemia [5, 6] 
and lymphoblastic leukemia [7]. Under normal conditions, 
HO-1 is carboxy-terminally anchored to the endoplasmic 
reticulum (ER), but under stress conditions, for example 
under hypoxia, it is cleaved and translocates to the cytosol 
and nucleus [8, 9]. Translocation disrupts the association 
of HO-1 with the electron donating enzyme cytochrome 
P450 reductase (CPR) [8, 9]. This reduces heme degrading 
catalytic activity to very low levels [9]. Recently, HO-1 
translocation was found to be mediated by signal peptide 
peptidase (SPP) [10, 11]. High levels of translocated HO-1 
were observed in cell lines with high SPP expression [3, 11, 
12]. In head and neck squamous cell carcinoma [12] and 
multiple myeloma [13] nuclear HO-1 seems to play a role 
in malignant progression or drug resistance. Translocation 
of HO-1 to the cytosol and nucleus has been explicitly 
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linked to imatinib resistance in the chronic myelogenous 
leukemia cell line K562 [14]. To test whether imatinib 
resistance can be induced by overexpression of HO-1, we 
used this cell line as it is amenable to genetic manipulation 
and pharmacological testing.
Imatinib is a competitive inhibitor of the 
oncogenic tyrosine kinase BCR-ABL that causes chronic 
myelogenous leukemia (CML) [15–17]. Mutations in the 
BCR-ABL kinase domain can confer resistance to imatinib 
[18–21]. Beyond these classic cases of imatinib resistance, 
sensitivity to imatinib has been suggested to be influenced 
by HO-1, an enzyme that seems to have no connection to 
imatinib signaling at first sight. However, the observation 
that heme oxygenase is upregulated in myeloid leukemia 
[5, 6] and is induced by imatinib treatment [5], sparked 
interest. Further experiments showed that inhibition 
of HO-1’s catalytic activity with zinc protoporphyrine 
(ZnPP) could recover imatinib sensitivity in formerly 
resistant cells [6, 22]. Surprisingly, a recent study indicates 
that imatinib resistance is mediated by nuclear HO-1 
independent of its catalytic activity [14]. Thus, while 
all studies agree on a role of HO-1 in tumor progression 
and imatinib resistance, it is unclear whether this effect 
is mediated by the catalytic activity of HO-1 or its 
subcellular localization or a combination of both.
In the present study, we systematically investigated 
HO-1 mediated imatinib resistance in leukemia cells to 
analyze the relevance of HO-1’s catalytic activity and 
subcellular localization for the development of drug 
resistance. We created two different types of monoclonal 
stable K562 cell lines overexpressing GFP-tagged 
HO-1:cells with full length ER resident HO-1 and cells with 
an anchorless HO-1 mutant that localizes to the cytosol and 
nucleus representing a model for translocated HO-1. We 
found that overexpression of ER resident HO-1 alone does 
not cause imatinib resistance. However, two out of seven 
cell lines expressing anchorless, translocated HO-1 showed 
imatinib resistance. We conclude that translocated HO-1 
in the cytosol and nucleus seems to foster drug resistance 
while overexpression of ER resident HO-1 does not seem to 
have an influence on imatinib resistance.
RESULTS
Generation of cell models for ER anchored HO-1 
and anchorless HO-1
To analyze the role of HO-1 in imatinib resistance, 
we created monoclonal stable K562 cell lines expressing 
GFP-HO-1 or the anchorless construct GFP-HO-1-ΔC266. 
We additionally generated a monoclonal stable K562 cell 
line expressing GFP only as a control. The expression 
of GFP or the different HO-1 variants was confirmed 
by Western blot with specific anti-GFP and anti-HO-1 
antibodies. In addition, subcellular localization was 
analyzed using live cell imaging.
As expected, untransfected K562 cells did not show 
any signal at around 60 kDa, neither with GFP antibody 
nor with HO-1 antibody. The K562 GFP cell line showed 
a signal detected with GFP antibody at around 30 kDa, 
but no signal for detection with HO-1 antibody (Figure 
1A). All the GFP-fused HO-1 variants could be detected 
with GFP and HO-1 antibodies at a size of around 60 kDa 
(Figure 1B and 1C). Actin, which was used as loading 
control, was clearly detectable at around 40 kDa in all cell 
extracts (Figure 1). Some samples show a second band 
below the GFP-fused HO-1 construct. Such double bands 
have also been observed for HO-1 (but not HO-2) after 
expression in the baculovirus / Sf9 expression system [9]. 
It is unlikely that the lower band represents a carboxy-
terminal degradation product of HO-1 as described by 
Yoshida et al. [23], because the carboxy-terminally 
deleted GFP-HO-1-ΔC266 shows a similar second band 
(Figure 1C and [9]). It is rather likely that the lower band 
represents a different post-translationally modified version 
of HO-1.
In addition, the subcellular localization of GFP and 
the GFP-fused HO-1 constructs was analyzed by confocal 
laser scanning microscopy (Figure 2). As expected, 
GFP is distributed in nucleus and cytosol (Figure 2A). 
Monoclonal stable K562 cell lines expressing GFP-HO-1 
all show the typical ER localization of GFP-fused wild 
type HO-1 (Figure 2B; cell lines 1-6). Notably, the nucleus 
is free of GFP-HO-1. In contrast, monoclonal stable K562 
cell lines expressing GFP-tagged anchorless HO-1 all 
show cytosolic and nuclear localization (Figure 2C; cell 
lines 7-13) similar to translocated GFP-HO-1 [9].
ER anchored HO-1 translocates under hypoxia 
in monoclonal stably transfected K562 cells
HO-1 can be cleaved under stress conditions and 
subsequently translocates to the cytosol and nucleus 
[8-11]. To investigate whether this specific behavior of ER 
anchored HO-1 is also observed in our K562 cell model, 
we incubated our monoclonal stably transfected cells for 
48 h under hypoxic conditions (1 % O2). We observed 
translocation of ER anchored HO-1 to the cytosol and 
nucleus in all six cell lines (Figure 3). After incubation 
under hypoxia, cell lines 1-6 showed the same distribution 
of the GFP fused HO-1 as cell lines 7-13, which mimic 
translocated HO-1. This shows that our GFP-HO-1 variant 
is able to translocate in K562 cells and that translocated 
GFP-HO-1 has the same phenotype as our anchorless 
model construct GFP-HO-1-ΔC266.
ER anchored HO-1 catabolizes heme more 
efficiently than the anchorless HO-1 variant
In comparison to other commonly used cell lines, 
K562 tolerate high hemin levels. When incubated with 
hemin K562 cells start to synthesize hemoglobin. With 
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increasing synthesis of hemoglobin in K562 cells, a 
change in color from white to red is observed. In cell 
extracts the typical spectrum of hemoglobin with the 
Soret band at 415 nm and the two smaller α- and β-bands 
at 542 nm and 577 nm can be measured by UV-Vis 
spectrophotometry [24] (Figure 4). We used this property 
of K562 to draw conclusions about the activity of the 
GFP-fused HO-1 variants. When transfected active HO-1 
catabolizes heme, less hemin is left for the formation of 
hemoglobin in comparison to untransfected cells. This 
should result in a smaller Soret peak of hemoglobin in the 
absorbance spectra and a shift of the color of the cell pellet 
from red to white.
As expected, the two control cell lines, untransfected 
K562 and GFP expressing K562, both have red colored 
cell pellets and similar hemoglobin spectra (Figure 4). All 
monoclonal stable K562 cell lines with the construct GFP-
HO-1 show less colored cell pellets than untransfected 
K562 and a decrease in the Soret band measured by UV-
Vis spectroscopy (Figure 5; cell lines 1-6). Cell lines 
expressing the anchorless variant also have whiter cell 
pellets and a smaller Soret band than untransfected K562 
(Figure 6; cell lines 7-13). This indicates that both types 
of HO-1 constructs are active as a portion of hemin is 
catabolized and not available for hemoglobin formation. 
Based on inspection of cell pellets, cell lines expressing 
Figure 1: Analysis of protein expression of the generated monoclonal stable K562 cell lines by Western blot. The correct 
protein expression of the newly generated monoclonal stable K562 cell lines was analyzed by SDS-PAGE of cell extracts, followed by 
Western blot, detected with specific GFP and HO-1 antibodies. Actin was detected as loading control. (A) Controls-: Untransfected K562. 
GFP: Stable K562 cell line expressing GFP. (B) ER resident K562 GFP-HO-1 1-6. (C) Anchorless variant K562 GFP-HO-1-ΔC266 7-13. 
Left and right: ladder [kDa].
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Figure 2: Analysis of the subcellular localization of GFP, GFP-HO-1 and GFP-HO-1-ΔC266 in the positively 
characterized stable K562 cell lines by confocal laser scanning microscopy. (A) In the monoclonal stable K562 cell line 
expressing GFP, the protein is distributed in cytosol and nucleus. (B) In the monoclonal stable K562 cell lines 1-6 GFP-HO-1 is localized at 
the ER membrane. The nucleus is free from GFP-HO-1. (C) In the monoclonal stable K562 cell lines 7-13 GFP-HO-1-ΔC266 is distributed 
in cytosol and nucleus. Figure shows representative data from three pictures per sample measured on a CLSM at 37 °C. Bar represents 
20 μm.
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the anchorless HO-1 construct seem to have weaker HO-1 
activity in comparison to cell lines expressing the full 
length ER anchored HO-1.
To quantify the reduction of hemoglobin synthesis 
upon HO-1 expression, we calculated the area under the 
curve (AUC) of the Soret peak at 415 nm. As expected 
untransfected K562 and K562 GFP synthesized similar 
amounts of hemoglobin (Figure 7A), because both lack 
overexpressed HO-1. Data of cell lines expressing the 
same construct were averaged to compare the activity of 
K562 cells expressing ER resident HO-1 or anchorless 
HO-1 with untransfected K562 cells (Figure 7B). Both 
constructs lead to a decrease in hemoglobin formation 
due to hemin catabolism by HO-1, when compared with 
untransfected K562. However, ER anchored HO-1 had 
higher activity than the anchorless variant compared 
to untransfected K562 cells. This is shown by the 
significantly lower AUC value of the Soret peak, while 
the group with the nuclear and cytosolic HO-1 just 
shows a moderate decrease that does not reach statistical 
significance.
K562 cell lines expressing ER anchored full 
length HO-1 show sensitivity to imatinib
To analyze the effect of ER resident overexpressed 
HO-1 in K562 cells on imatinib resistance we measured 
cell viability with an MTT based cell viability assay of 
all monoclonal stable K562 cell lines and untransfected 
K562 or K562 GFP as controls. Dose-response curves 
of K562 cells expressing the ER anchored HO-1 variant 
were generated (Figure 8A) and the corresponding IC50 
values are given in Table 1 (IC50, mean ± SEM). The 
IC50 values of cell lines expressing ER anchored HO-1 lie 
between 3.78 ± 1.33 μM and 7.08 ± 1.35 μM and are well 
within the range of the IC50 value of untransfected cells 
Figure 3: Analysis of the subcellular localization of GFP-HO-1 in the positively characterized stable K562 cell lines 1-6 
after 48 h hypoxia (1 % O2) by confocal laser scanning microscopy. Under normoxia GFP-HO-1 is localized at the ER membrane. 
The nucleus is free from GFP-HO-1. After 48 h incubation under hypoxia GFP-HO-1 translocated to cytosol and nucleus. Figure shows 
representative data from five pictures per sample out of three independent experiments on a CLSM at 37 °C. Bar represents 20 μm.
Figure 4: Hemoglobin synthesis experiments in a K562 cell line expressing GFP. Cell pellets and hemoglobin absorbance 
spectra of a K562 cell line expressing GFP in comparison to untransfected K562. Cells were incubated for 5 days at 37 °C and 5 % CO2 in 
K562 media. Grey curve: no media supplement. Red curve: supplement of 40 μM hemin. -: Untransfected K562. GFP: K562 expressing 
GFP. Cell pellets and spectra from one representative measurement are shown.
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Figure 5: Hemoglobin synthesis experiments in K562 cell lines expressing ER anchored HO-1. Cell pellets and hemoglobin 
absorbance spectra of different K562 cell lines expressing the ER anchored HO-1 variant GFP-HO-1. Cells were incubated for 5 days at 
37 °C and 5 % CO2 in K562 media. Grey curve: no media supplement. Red curve: supplement of 40 μM hemin. -: Untransfected K562. 1-6: 
K562 expressing GFP-HO-1. Cell pellets and spectra from one representative measurement are shown.
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Figure 6: Hemoglobin synthesis experiments in K562 cell lines expressing anchorless HO-1. Cell pellets and hemoglobin 
absorbance spectra of different K562 cell lines expressing the anchorless HO-1 variant GFP-HO-1-ΔC266. Cells were incubated for 5 days 
at 37 °C and 5 % CO2 in K562 media. Grey curve: no media supplement. Red curve: supplement of 40 μM hemin. -: Untransfected K562. 
7-13: K562 expressing GFP-HO-1-ΔC266. Cell pellets and spectra from one representative measurement are shown.
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(2.87 ± 1.41 μM) or K562 GFP (2.35 ± 1.38 µM). Taken 
together this indicates that all cell lines with ER anchored 
full length HO-1 show sensitivity to imatinib treatment 
just like untransfected K562 cells or K562 GFP.
K562 cell lines expressing anchorless HO-1 may 
develop resistance against imatinib
To evaluate the role of the anchorless HO-1 in 
imatinib resistance, we measured dose-response curves 
(Figure 8B) and determined IC50 values (Table 1). Five 
cell lines (8, 9, 10, 11 and 13) showed IC50 values from 
2.92 ± 1.30 μM to 7.57 ± 1.26 μM that were again similar 
to the IC50 value of untransfected cells or K562 GFP. 
However, two cell lines (7 and 12) showed significantly 
higher IC50 values: 19.76 ± 1.19 μM and 12.35 ± 1.57 
μM, respectively. Hence, cell lines expressing anchorless 
HO-1 can be divided into two groups: imatinib sensitive 
and imatinib resistant cell lines.
Cell morphology confirms imatinib sensitivity or 
resistance of selected K562 cell lines
To validate these findings, one representative cell 
line from each group was selected for confocal laser 
scanning microscopy. Cells were imaged untreated 
and after treatment with 10 μM imatinib for 24 h. The 
imatinib concentration of 10 μM corresponds to a 
Figure 7: Comparison between HO-activity of untransfected or GFP expressing control cells and K562 cell lines 
expressing ER resident HO-1 or the anchorless HO-1 variant. AUCs of the Soret peak at 415 nm were calculated for each cell 
line. (A) Data from four independent experiments were averaged per group to compare the HO-activity in untransfected K562 with K562 
expressing GFP. (B) Data from four independent experiments were averaged per group to compare the HO-activity in untransfected K562 
with the HO-activity in cell lines expressing ER anchored GFP-HO-1 and anchorless GFP-HO-1-ΔC266. Error bars show the SEM. * 
significant compared to untransfected K562 (p<0.05).
Oncotarget9www.impactjournals.com/oncotarget
plasma concentration of 5897 ng / ml. Trough plasma 
concentrations of imatinib are in the range of 1000 ng / 
ml [25]. The highest reported peak plasma concentration 
(Cmax) of imatinib in CML patients was 4478 ng / ml in a 
study on pharmacokinetics of imatinib [26]. The chosen 
concentration of 5897 ng / ml therefore would probably be 
reached only with exceptionally high doses in patients and 
thus represents a good test dose for imatinib resistance. 
No change in morphology was observed in the imatinib 
resistant K562 cell line 7 expressing anchorless HO-1 
(Figure 9). In contrast, all other tested cell lines showed 
morphological signs of apoptosis which is seen best in 
the differential interference contrast (Figure 9, DIC). 
This indicates that anchorless HO-1 can promote imatinib 
resistance in concert with other factors that is likely 
clinically relevant.
DISCUSSION
An altered expression of HO-1 in cancer and 
leukemic cells was observed in several studies [2-4, 27]. 
In addition, HO-1 translocation from the ER to the cytosol 
and nucleus has been reported [3, 11-14]. Whether HO-1 
represents just a marker of neoplastic disease, or whether 
there is a causal relationship between HO-1 and malignant 
growth is unclear until now. However, it is this distinction 
that decides whether HO-1 is indeed a promising novel 
target of cancer therapy [1]. Translocation of HO-1 to the 
Figure 8: Dose-response curves of cell lines expressing ER resident or anchorless HO-1 treated with imatinib. (A) 
Dose-response curves for cell lines expressing ER anchored GFP-HO-1. (B) Dose-response curves for cell lines expressing the anchorless 
HO-1 variant GFP-HO-1-ΔC266. Dose-response curves of untransfected K562 and K562 GFP are added to both graphs for comparison. 
The curves show data from triplicate measurements of at least three independent experiments and the calculated dose-response curves for 
each cell line. Error bars show the SEM.
Oncotarget10www.impactjournals.com/oncotarget
cytosol and nucleus has been explicitly linked to imatinib 
resistance in the chronic myelogenous leukemia cell 
line K562 [14]. To challenge these findings, we decided 
to study whether imatinib resistance can be induced by 
overexpression of HO-1 variants. Our results show that 
overexpression of full length ER resident HO-1 has no 
effect on imatinib resistance. However, overexpression of 
an HO-1 variant mimicking translocated HO-1 (anchorless 
HO-1) resulted in imatinib resistance in two out of seven 
cell lines. This is in full agreement with the findings of 
Tibullo et al. showing that the translocated, anchorless 
HO-1 causes imatinib resistance, rather than the ER 
resident form [14].
The observation that only two out of seven cell lines 
were resistant clearly shows that anchorless HO-1 is not 
a direct cause of imatinib resistance. However, it is in 
fact a high percentage of resistant cells from the clinical 
perspective as CML patients have to take imatinib for 
a long period. To develop a clinically relevant imatinib 
resistance one single resistant cell is enough, because 
imatinib sensitive leukemia cells are killed regularly and 
imatinib resistant leukemia cells survive and accumulate 
over time [20, 28]. This is a well-known principle in long 
term hematological-oncological therapy with tyrosine 
kinase inhibitors [29]. For example in a study with 85 
CLL (chronic lymphocytic leukemia) patients treated with 
the Bruton’s tyrosine kinase (BTK) inhibitor ibrutinib 7 
patients developed Richter`s transformation, a more 
aggressive lymphoma form, during ibrutinib treatment 
[30].
Our findings show that overexpression of 
anchorless HO-1 alone is not sufficient to cause imatinib 
resistance. A possible explanation is that translocated 
HO-1 has an effect on an intervening factor that causes 
imatinib resistance with some variability. This idea 
would fit to more recent work by Tibullo et al. who 
showed that nuclear HO-1 promotes genomic instability 
in malignant cells [13]. This is also in line with signs 
of imatinib resistance occurring as a consequence of 
somatic mutations in some but not all cell lines. Nuclear 
HO-1 has been shown to interact with Nrf2 (NF-E2 
related factor 2) [31] and additional transcription factors 
such as STAT3, CDP, Brn-3, CBF and AP-2 [8]. Thus, a 
direct or indirect influence on DNA repair mechanisms is 
well conceivable [13].
It cannot be ruled out completely that inactivation of 
unrelated genes due to genomic integration of constructs 
has an influence on imatinib resistance. Nevertheless, it 
is unlikely that coding genes are inactivated, it is very 
unlikely that these coding genes have an influence on 
imatinib resistance and it is extremely unlikely that this 
happens twice and only in cell lines overexpressing the 
Table 1: IC50 values of the tested monoclonal stable K562 cell lines and untransfected K562
Cell line IC50
[μM]
SEM IC50
[μM]
IC50
[ng/ml]
SEM IC50
[ng/ml]
K562 GFP 2.35 1.38 1386 814
K562 - 2.87 1.41 1692 831
K562 GFP-HO-1 1 3.78 1.33 2229 784
K562 GFP-HO-1 2 5.68 1.22 3349 719
K562 GFP-HO-1 3 5.19 1.23 3061 725
K562 GFP-HO-1 4 6.07 1.24 3579 731
K562 GFP-HO-1 5 5.99 1.27 3532 749
K562 GFP-HO-1 6 7.08 1.35 4175 796
K562 GFP-HO-1-ΔC266 7 19.76 * 1.19 11652 * 702
K562 GFP-HO-1-ΔC266 8 3.72 1.30 2193 767
K562 GFP-HO-1-ΔC266 9 7.57 1.26 4464 743
K562 GFP-HO-1-ΔC266 10 3.96 1.54 2335 908
K562 GFP-HO-1-ΔC266 11 5.65 1.41 3332 831
K562 GFP-HO-1-ΔC266 12 12.35 * 1.57 7283 * 926
K562 GFP-HO-1-ΔC266 13 2.92 1.30 1722 767
The first column shows the name of the tested cell line, the second and fourth column the determined IC50 value as mean 
of at least three independent experiments in μM or ng/ml, the third and fifth column the SEM of the IC50 in μM or ng/ml. 
* significant increase of IC50 compared to untransfected K562 or K562 GFP (p<0.05).
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anchorless construct GFP-HO-1-ΔC266 but not in cell 
lines expressing GFP-HO-1 or GFP.
Our finding that overexpression of ER resident 
HO-1 does not lead to imatinib resistance, argues against 
the idea that products of the enzymatic heme oxygenase 
reaction such as biliverdin / bilirubin or the gaseous 
molecule carbon monoxide induce imatinib resistance. 
It is rather likely that mutations in other signal pathways 
of the leukemic cell together with imatinib treatment, 
lead to upregulation of HO-1 in the leukemic cell. This 
might allow the cell to cope with imatinib toxicity and the 
metabolic derangements typical of malignant cells [32].
HO-1 enables renal carcinoma cells with a defect 
in fumarate hydratase to proliferate despite the defect in 
the tricarboxylic acid cycle [27]. In this study, HO-1 was 
said to be synthetically lethal with the tumor suppressor 
fumarate hydratase [27]. Two genes are synthetically 
lethal if mutation of either alone is compatible with 
viability but mutation of both leads to death [33]. This 
represents a unique opportunity because targeting a gene 
that is synthetically  lethal to a cancer-relevant mutation 
should kill only cancer cells and spare normal cells 
[33]. In analogy to a cancer relevant mutation (such as 
the BCR-ABL oncogene) that leads to a compensating 
HO-1 increase, imatinib treatment can also lead to a 
similar compensating HO-1 increase. In both cases, the 
compensating gene represents a promising drug target 
or co-target. This idea is supported by the finding that 
inhibition of HO-1 induces apoptosis in BCR-ABL-
positive B-ALL (acute lympohoblastic leukemia) and 
increases the sensitivity to treatment by imatinib [34]. 
Similarly, HO-1 has recently been found to be upregulated 
Figure 9: Confocal laser scanning microscopy of selected imatinib treated K562 cell lines. (A) Untreated. (B) 24 hours after 
incubation with 10 μM imatinib. Figure shows representative data from five pictures per sample out of three independent experiments on a 
CLSM at 37 °C. DIC: differential interference contrast. Bar represents 20 μm.
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in pancreatic cancer treated with imatinib [35] and was 
also suggested as co-target of imatinib treatment.
It has previously been shown that anchorless HO-1 
is less active than ER anchored HO-1 [8]. We can confirm 
this with our hemoglobin synthesis experiments. In cell 
lines expressing anchorless HO-1 more hemoglobin 
could be synthesized than in cell lines expressing ER 
anchored HO-1. Hence, ER resident GFP-HO-1 had 
higher heme catabolizing activity than the anchorless 
variant GFP-HO-1-ΔC266. The reason for this lies in 
the subcellular localization of HO-1. CPR is the electron 
donor for heme catabolism [36] and is located at the ER 
membrane. Although anchorless HO-1 still contains the 
CPR and BVR (biliverdin reductase) binding sites [37, 38], 
it is less likely to form a complex with CPR as HO-1’s ER 
anchor increases CPR binding affinity [39, 40]. Interaction 
of CPR with anchorless HO-1 is still possible in the 
cytosol, but very unlikely in the nucleus. However, there 
may be alternative electron donors in the nucleus which 
may provide electrons to translocated HO-1, since it has 
been shown that modulation of some transcription factors 
by nuclear HO-1 depend on heme degrading activity [8].
Heme induced hemoglobin synthesis in K562 
cells also reflects erythroid differentiation of the 
megakaryocyte-erythroid bone marrow progenitor cell 
[24, 41]. It has been shown that erythropoietin protects 
leukemia cells from imatinib-induced killing by promoting 
erythroid differentiation [42]. This is in line with the 
effect of heme which promotes both imatinib resistance 
and erythroid differentiation [28]. Results from Jacquel et 
al. indicate that imatinib treatment of K562 cells either 
leads to apoptosis or erythroid differentiation [43]. Taken 
together erythroid differentiation may play a role in HO-1 
mediated drug resistance, although our experiments do not 
indicate any correlation between hemoglobin formation 
from supplemented hemin and imatinib resistance.
In summary, we suggest that HO-1 plays a dual 
role in imatinib resistant CML: endogenous ER resident 
HO-1 can represent a survival factor for leukemic cells, 
but overexpression of ER resident HO-1 does not lead 
to imatinib resistance, whereas translocation of HO-1 
to the nucleus and cytosol supports imatinib resistance 
in some but not all cell lines. We conclude that further 
studies should focus on the potential of inhibiting the 
translocation mechanism of HO-1. This might be achieved 
by the avoidance of hypoxia and the use of SPP inhibitors 
and may represent a general strategy for the prevention 
of genomic instability and drug resistance of cancer cells.
MATERIALS AND METHODS
Materials
Unless stated otherwise, chemicals were purchased 
in high purified quality from Sigma-Aldrich Chemie 
GmbH (Steinheim, Germany), Applichem GmbH 
(Darmstadt, Germany) or Serva Electrophoresis GmbH 
(Heidelberg, Germany). Cell culture media were received 
from Life Technologies GmbH, Invitrogen™ (Darmstadt, 
Germany) or BIO & Sell e. K. (Feucht, Germany).
Cloning of HO-constructs
GFP-HO-1 and the anchorless construct GFP-HO-1-
ΔC266 were cloned as described before [9] corresponding 
to the UniProt accession code P09601.
Cell culture
K562 were purchased from DSMZ (Leibniz Institute 
DSMZ, German Collection of Microorganisms and Cell 
Cultures, Braunschweig, Germany, DSMZ-No. ACC 
10) [41]. They were cultivated in RPMI (Roswell Park 
Memorial Institute) 1640 with 10 % fetal bovine serum 
and 1 % Penicillin/Streptomycin at 37 °C with 5 % CO2. 
For cultivation of stable K562 cell lines 1 % G418 was 
added.
Generation and characterization of monoclonal 
stable K562 cell lines
Stable K562 cell lines were created as described in 
Zeyda et al. [44]. Transient transfection of K562 cells was 
made by electroporation with Neon® Transfection System 
(Thermo Fisher Scientific, Walthram, USA) according to 
manufacturer’s recommendations. Freshly electroporated 
cells were kept in media without antibiotics. 48 h after 
transient transfection cells were sorted for the first time. 
GFP+ cells were kept and cultivated in RPMI 1640 with 
10 % fetal bovine serum and 1 % Penicillin/Streptomycin 
+ 1 % G418. Sorting of GFP+ cells in a batch was done for 
two more times, each after 10-12 more days of cultivation. 
After a minimum of three batch sorts, single GFP+ cells 
were seeded into 96 well plates for achieving monoclonal 
stable cell lines. Cell sorting was carried out on a BD FACS 
Aria II (Becton Dickinson GmbH, Heidelberg, Germany) 
at the platform for flow cytometry of the Helmholtz 
Center for Infection Research, Braunschweig, Germany. 
All monoclonal stable K562 cell lines were screened for 
GFP and HO-1 expression by Western blot analysis with 
specific anti-GFP and anti-HO-1 antibodies and correct 
localization of the HO-1 variant using live cell imaging. In 
cell lines expressing ER anchored HO-1 hypoxia mediated 
translocation was additionally tested. Just positively 
characterized cells were included in further experiments.
Cell extracts
Cell extracts were made by sonification of K562 
cells (Sonoplus HD 2070, Bandelin electronic GmbH & 
Co. KG, Berlin, Germany) in TEA (triethanolamine)-lysis-
buffer (50 mM TEA, 1 mM EDTA, pH=7.4) containing 
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one tablet cOmplete protease inhibitor cocktail per 
50 ml (Roche Diagnostics Deutschland GmbH, Mannheim, 
Germany) and subsequent centrifugation for 30 min at 
21 000 x g and 4 °C. Overall protein concentration of the 
cell extracts were determined by Bradford assay [45].
SDS-PAGE and Western blot
For Western blot analysis cell extracts containing 
90 μg protein and the equivalent volume of sodium dodecyl 
sulphate (SDS) sample-buffer (1 % SDS, 100 mM DTT 
(Dithiotreitol), 50 mM Tris, 30 % Glycerol, pH=7.5) 
were used. The samples were cooked for 3 min at 99 °C. 
Afterwards bromophenol blue was added and the samples 
were loaded on 10 % gels. PageRuler™ Prestained Protein 
Ladder and PageRuler™ Unstained Protein Ladder (Thermo 
Scientific, Walthram, USA) were used for size control. After 
SDS-PAGE gels were blotted on nitrocellulose membranes, 
stained with Ponceau S and blocked for at least 1 hour in 
TBST (Tris-buffered saline with Tween®20) buffer (10 mM 
Tris–HCl, 150 mM NaCl, 0.1 % Tween® 20, pH=8.0) 
containing 5 % non-fat dry milk. For detection we used used 
rabbit-anti-HO-1 (1:5000, Stressgen, Enzo Life Sciences, 
Lörrach, Germany), rabbit-anti-GFP (1:2000, Clontech 
Laboratories, Inc., Mountain View, USA) and mouse-anti-
actin (1:2000, Sigma-Aldrich Chemie GmbH, Steinheim, 
Germany). As secondary antibody we used horseradish 
peroxidase-conjugated anti-rabbit or anti-mouse IgGs 
(1:2000, Cell Signaling Technology, Inc., Danvers, USA). 
HO-1 antibody was diluted in TBST buffer, containing 
1 % non-fat dry milk, all other antibodies were diluted in 
TBST buffer. The membranes were incubated for 1-2 h at 
room temperature with primary antibodies, washed three 
times for 5 minutes with TBST and then incubated with 
the secondary antibodies for 45 min. After another three 
washing steps the membranes were detected with Lumi-
LightPLUS Western Blotting Substrate (Roche Diagnostics 
Deutschland GmbH, Mannheim, Germany) according to 
manufacturer`s recommendations in an ECL ChemiLux 
Imager (Intas, Göttingen, Germany).
Live Cell Imaging
Stable transfected K562 cell lines were imaged 
at 37 °C on a Nikon Ti-E microscope equipped with an 
incubation chamber (Okolab) using a 60 x oil immersion 
objective (NA 1.4, Nikon). A focused 488 nm laser was used 
for GFP excitation. Emission was measured between 500-550 
nm. For translocation experiments all cell lines expressing 
GFP-HO-1 were imaged before and after incubation under 
hypoxia (1 % O2) for 48 h. For cell viability experiments 
selected cell lines were incubated with 10 μM imatinib for 24 
h, imaged and compared to cells without imatinib stimulation. 
For data collection and picture editing we used NIS-Elements 
Ar Microscope Imaging Software (Nikon Instruments Europe 
BV, Amsterdam, Netherlands).
Hemoglobin formation experiments
1 Million cells per sample of untransfected K562 
and stable transfected K562 cell lines were cultivated at 
37 °C and 5 % CO2 in RPMI 1640 with 10 % fetal bovine 
serum and 1 % Penicillin/Streptomycin once with, once 
without the supplement of 40 μM hemin. Five days later 
the cells were centrifuged at 900 x g, 4 °C for 5 min, the 
supernatant was refused and the pellet was washed in 1 ml 
PBS (phosphate-buffered saline). After washing cells were 
centrifuged at 2000 x g, 4 °C for 5 min and the pellet was 
photographed. After removing the supernatant cells were 
resuspended in 500 μl fresh PBS, sonified as described 
above and centrifuged at 15000 x g, 4 °C for 30 min. 
Absorbance spectra of the supernatants were measured 
on a UV-Vis spectrophotometer Cary 50 (Varian/Agilent 
Technologies, Waldbronn, Germany).
Cell viability assay
20000 cells per well were seeded in RPMI 1640 
with 10 % fetal bovine serum and 1 % Penicillin/
Streptomycin in 96 well plates. The next day they were 
stimulated with increasing concentrations of imatinib 
(0/0.1/1/5/10/100 μM) and cultivated for 22 more 
hours, before MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium-bromide) was added. After incubation 
for 2 more hours cells were harvested and resuspended 
in extraction buffer (DMF (dimethylformamide) / H2O 
(v/v) 1:1, 10 % SDS (w/v)). Cell viability was measured 
colorimetric at 550 nm on a Sunrise™ Absorbance Reader 
(Tecan Deutschland GmbH, Crailsheim, Germany). Data 
was calculated as ratio to untreated control.
Statistical analysis
Data values of at least three independent 
experiments were analyzed by one-way ANOVA (analysis 
of variance) followed by paired student`s t-test versus 
untransfected K562 or K562 GFP. P-values <0.05 (*) were 
considered significant. Data are presented with indicated 
error bars showing ± SEM.
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